TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25736957

Group type: EXPERIMENTAL
Intervention: Hip strengthening exercises
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hip rotation stretching exercises
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multi-directional hip stretching exercises
Number of subjects: 30
Study: 23887741

Group type: EXPERIMENTAL
Intervention: Levosimendan infusion at 0.1 μg/kg/min, every 30 days
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 21145540

Group type: EXPERIMENTAL
Intervention: Laparoscopy to diagnose endometriosis, assessment by neurologist to assess headaches
Number of subjects: 108
Study: 19175042

Group type: EXPERIMENTAL
Intervention: ThermoStapler vessel sealing system (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard surgical technique (n = 60)
Number of subjects: 120
Study: 17121211

Group type: COMPARATOR
Intervention: Duloxetine 60 mg once a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duloxetine 60 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 0
Study: 12826965

Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 60
Study: 10694193

Group type: EXPERIMENTAL
Intervention: L-arginine (15 g/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 9017786

Group type: EXPERIMENTAL
Intervention: Pharmacologic agents that reduce leukotriene activity or enhance prostaglandin activity, or agents that do both; specific agents not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-agonists and cromolyn sodium; specific dosages and durations not mentioned.
Number of subjects: 0
Study: 8446805

Group type: EXPERIMENTAL
Intervention: Multivariate models for crossover designs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Univariate methods
Number of subjects: 0
Study: 3511772

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 28598590

Group type: EXPERIMENTAL
Intervention: Corega group (CG)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Renew group (RG)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Distilled water group (DWG)
Number of subjects: 81
Study: 28913920

Group type: EXPERIMENTAL
Intervention: Dramatic pretend play games
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 97
Study: 26569461

Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DT)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: No Defibrillation Testing (No DT)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Postoperative Troponin Levels Above ULN (both DT and No DT)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Postoperative Troponin Levels (both DT and No DT)
Number of subjects: 2500
Study: 25100359

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone treatment for 36 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo patch for 36 months
Number of subjects: 108
Study: 22581698

Group type: EXPERIMENTAL
Intervention: CO₂ insufflation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 180
Study: 20557819

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Resistive training
Number of subjects: 22
Study: 17586413

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 34
Study: 15918385

Group type: COMPARATOR
Intervention: General anaesthesia with isoflurane/nitrous oxide (group General)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anaesthesia combined with isoflurane/nitrous oxide (group Integrated)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of heart rate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of mean arterial pressure
Number of subjects: 40
Study: 14657746

Group type: EXPERIMENTAL
Intervention: Closed suction drainage
Number of subjects: 30

Group type: COMPARATOR
Intervention: No closed suction drainage (Control)
Number of subjects: 30
Study: 10533793

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFNalpha) treatment
Number of subjects: 18
Study: 8649056

Group type: EXPERIMENTAL
Intervention: HDT plus ASCT
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional chemotherapy (CT)
Number of subjects: 55
Study: 1676238

Group type: EXPERIMENTAL
Intervention: bisoprolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 7107353

Group type: COMPARATOR
Intervention: MISO alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: MISO with DXM
Number of subjects: 14
Study: 31817052

Group type: EXPERIMENTAL
Intervention: Continuous energy restriction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction
Number of subjects: 0
Study: 29780293

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF) followed by infusion of autologous mobilized peripheral blood mononuclear cells (mPBMCs)
Number of subjects: 16
Study: 27059880

Group type: EXPERIMENTAL
Intervention: Bilateral anodal and cathodal transcranial direct current stimulation (tDCS) applied to the left and right dorsolateral prefrontal cortex (dLPFC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral tDCS over the dLPFC
Number of subjects: 0
Study: 24655586

Group type: EXPERIMENTAL
Intervention: Hatha yoga as add-on treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Quetiapine fumarate extended release (QXR) 300 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Escitalopram (ESC) 10 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cortisol improvers in week 1 of therapy
Number of subjects: 60
Study: 22677580

Group type: EXPERIMENTAL
Intervention: StepStone Interactive Medical Software (SS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional lecture format (Control)
Number of subjects: 30
Study: 21162438

Group type: EXPERIMENTAL
Intervention: Group 1 (n = 55) with one constraint
Number of subjects: 108

Group type: COMPARATOR
Intervention: Group 2 (n = 53) with three constraints
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 17546332

Group type: EXPERIMENTAL
Intervention: 200mg iron sulfate alone (40 mg elemental iron) for 30 weeks
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 200mg iron sulfate plus 10,000 IU of vitamin A for 30 weeks
Number of subjects: 267

Group type: COMPARATOR
Intervention: Comparison of mean Hb and anemia prevalence between groups
Number of subjects: 267
Study: 15705659

Group type: EXPERIMENTAL
Intervention: 1-(13)C-labeled l-leucine infusion
Number of subjects: 12
Study: 12163729

Group type: EXPERIMENTAL
Intervention: Cervical rib presence
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Sacralization presence
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Cervical rib with or without articulation
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Cervical rib with articulation
Number of subjects: 324
Study: 10088595

Group type: COMPARATOR
Intervention: Therapeutic procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two treatments
Number of subjects: 0
Study: 8848187

Group type: EXPERIMENTAL
Intervention: Bromocriptine (15 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1970108

Group type: EXPERIMENTAL
Intervention: Autolymphocyte therapy (ALT) plus oral cimetidine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cimetidine alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Autolymphocyte therapy (ALT)
Number of subjects: 90
Study: 7425360

Group type: EXPERIMENTAL
Intervention: Methohexital 20 mg/kg, rectally
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Methohexital 25 mg/kg, rectally
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Methohexital 30 mg/kg, rectally
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Methohexital (all doses)
Number of subjects: 99
Study: 30309264

Group type: EXPERIMENTAL
Intervention: Copeptin levels at admission
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Copeptin levels at discharge
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Copeptin levels after 3 months
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor binding protein-1 levels
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Copeptin as a predictor of cardiovascular events
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Cardiovascular events
Number of subjects: 393
Study: 29039872

Group type: EXPERIMENTAL
Intervention: Consistent vitamin D supplementation
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Inconsistent vitamin D supplementation
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: No vitamin D supplementation
Number of subjects: 573

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 573
Study: 24007304

Group type: EXPERIMENTAL
Intervention: Mavoglurant (AFQ056) 25 mg bid to 100 mg bid
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mavoglurant (AFQ056)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 25153733

Group type: EXPERIMENTAL
Intervention: Exercise intervention (n = 14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 27
Study: 22012805

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 20
Study: 19571161

Group type: EXPERIMENTAL
Intervention: quercetin+vitamin C (166mg+133mg/capsule)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: alpha‐lipoic acid (300mg/capsule)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 17533206

Group type: EXPERIMENTAL
Intervention: Structured pharmacist medication history interview with assessment and generation of a postoperative medication order form
Number of subjects: 464

Group type: COMPARATOR
Intervention: Standard care (nurse‐conducted medication histories and surgeon‐generated medication orders)
Number of subjects: 464
Study: 15302780

Group type: EXPERIMENTAL
Intervention: Reduction in albuminuria
Number of subjects: 1513
Study: 11347834

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Enoxaparin)
Number of subjects: 36
Study: 9389842

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uncuffed tracheal tube (TT)
Number of subjects: 30
Study: 8255974

Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion (0.5-3.0 micrograms/min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 25 mg atenolol (beta 1 antagonist)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 5 mg nadolol (beta 1/beta 2 blocker)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 80 mg nadolol (beta 1/beta 2 blocker)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion
Number of subjects: 7
Study: 3318433

Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg at bedtime
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin 900 mg four times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 40
Study: 29358034

Group type: EXPERIMENTAL
Intervention: Exercise group (n=20) engaged in 20min of combined aerobic and coordinative exercise on each school day for eight weeks.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wait-list control group (n=16) with no intervention.
Number of subjects: 36
Study: 27486125

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPH
Number of subjects: 0
Study: 25638594

Group type: EXPERIMENTAL
Intervention: Antral preserving‐LSG (AP‐LSG)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Antral resecting‐LSG (AR‐LSG)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Both groups (AP‐LSG and AR‐LSG)
Number of subjects: 113
Study: 23190785

Group type: EXPERIMENTAL
Intervention: Hib‐MenC‐TT coadministered with DTPa‐HBV‐IPV
Number of subjects: 709

Group type: COMPARATOR
Intervention: Control vaccines (MenC‐TT coadministered with DTPa‐HBV‐IPV/Hib)
Number of subjects: 709
Study: 21908754

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) treatment
Number of subjects: 393

Group type: COMPARATOR
Intervention: No intervention (control group: patients without legal problems)
Number of subjects: 393
Study: 17977950

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 16 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (14 matched control subjects)
Number of subjects: 24
Study: 12914871

Group type: EXPERIMENTAL
Intervention: Celecoxib (100 to 400 mg twice daily)
Number of subjects: 18942

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18942

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 18942
Study: 9888621

Group type: EXPERIMENTAL
Intervention: Zopiclone (ZOP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Flunitrazepam (FLU)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Self-report inventories
Number of subjects: 24
Study: 8554861

Group type: EXPERIMENTAL
Intervention: Conductive education-based programme (CE), duration: 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional early intervention programmes (Control), duration: 6 months
Number of subjects: 20
Study: 2922673

Group type: EXPERIMENTAL
Intervention: Billroth II
Number of subjects: 22

Group type: COMPARATOR
Intervention: Roux-en-Y
Number of subjects: 22
Study: 65278

Group type: EXPERIMENTAL
Intervention: Barbiturate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 30889250

Group type: EXPERIMENTAL
Intervention: Exercise plus dry needling (DN)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Exercise plus sham dry needling (sham DN)
Number of subjects: 62
Study: 31160249

Group type: EXPERIMENTAL
Intervention: Cediranib (30 mg orally, once daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 28390869

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sofosbuvir-velpatasvir for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir for 8 weeks and Sofosbuvir-velpatasvir for 12 weeks in patients with HCV genotype 3 and cirrhosis
Number of subjects: 0
Study: 25886377

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 755

Group type: COMPARATOR
Intervention: Usual care (GP care)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: SMS text messaging
Number of subjects: 755
Study: 23336742

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CO(2) laser
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study: 21365331

Group type: EXPERIMENTAL
Intervention: Contasure-Needleless (C-NDL)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Transobturator Tension-free vaginal tape (TVT-O)
Number of subjects: 158
Study: 19709417

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (120 mg/m2, d1) + Dacarbazine (175 mg/m2, d13)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vincristine, Epirubicin, Cyclophosphamide (control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-dacarbazine
Number of subjects: 31
Study: 17598312

Group type: EXPERIMENTAL
Intervention: Onsite adult vaccinations (intervention group)
Number of subjects: 186

Group type: COMPARATOR
Intervention: No vaccinations (comparison group)
Number of subjects: 186
Study: 15097265

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% (Trusopt)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Brimonidine 0.2% (Alphagan)
Number of subjects: 43
Study: 11531895

Group type: EXPERIMENTAL
Intervention: Needle acupuncture (verum)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 69
Study: 9692689

Group type: EXPERIMENTAL
Intervention: omeprazole 10 mg o.m.
Number of subjects: 674

Group type: COMPARATOR
Intervention: antacid/alginate liquid 10 mL q.d.s.
Number of subjects: 674
Study: 7836217

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2972158

Group type: EXPERIMENTAL
Intervention: Triphasic ethinyl estradiol/gestoden
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Monophasic ethinyl estradiol/desogestrel
Number of subjects: 10
Study: 31766943

Group type: EXPERIMENTAL
Intervention: Training with a broadband stimulus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active participation training strategy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Other training strategies (not specified)
Number of subjects: 40
Study: 31823786

Group type: EXPERIMENTAL
Intervention: Community mobilisation intervention
Number of subjects: 10112

Group type: EXPERIMENTAL
Intervention: Combined variable of intervention/high social capital
Number of subjects: 10112

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10112
Study: 27872061

Group type: EXPERIMENTAL
Intervention: RG7667
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26621715

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 100 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 22568744

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Minocycline microspheres (LDD)
Number of subjects: 40
Study: 21570516

Group type: EXPERIMENTAL
Intervention: Chest Pain Unit (CPU)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Admission to hospital
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Admitted from CPU
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Admitted after cardiac stress test in CPU
Number of subjects: 407

Group type: COMPARATOR
Intervention: Dismissed from CPU
Number of subjects: 407
Study: 19303793

Group type: EXPERIMENTAL
Intervention: On-pump CABG (ONCAB)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Both ONCAB and OPCAB
Number of subjects: 52
Study: 17387168

Group type: EXPERIMENTAL
Intervention: Community-based follow-up (n = 75)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Center-based follow-up (n = 75)
Number of subjects: 150
Study: 15252908

Group type: EXPERIMENTAL
Intervention: Home BP (n=203)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Office BP (n=197)
Number of subjects: 400
Study: 11465413

Group type: EXPERIMENTAL
Intervention: Microemulsion vehicle for lidocaine
Number of subjects: 8

Group type: COMPARATOR
Intervention: O/W emulsion-based cream for lidocaine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both active treatments (microemulsion and O/W emulsion)
Number of subjects: 8
Study: 9611474

Group type: EXPERIMENTAL
Intervention: Subgingival application of 25% metronidazole gel
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Subgingival scaling
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of scaling and metronidazole gel application
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (untreated quadrant)
Number of subjects: 13
Study: 7834161

Group type: EXPERIMENTAL
Intervention: Caffeine (2.5 mg.kg‐1 body weight)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ethanol (25 ml in 150 ml of grapefruit juice)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (grapefruit juice)
Number of subjects: 4
Study: 3202091

Group type: EXPERIMENTAL
Intervention: Vitamin A (3 mg RE or 10,000 IU daily for 4 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (daily for 4 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 30
Study: 31944804

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supportive listening
Number of subjects: 40
Study: 29171002

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel
Number of subjects: 1748

Group type: COMPARATOR
Intervention: Co-administration of carbamazepine and oxcarbazepine/phenytoin
Number of subjects: 1748

Group type: COMPARATOR
Intervention: CYP3A-inducing AEDs
Number of subjects: 1748
Study: 27708114

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo (non-users)
Number of subjects: 624
Study: 26208341

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 23860530

Group type: EXPERIMENTAL
Intervention: Aprepitant (day 1, 125 mg; days 2 and 3, 80 mg) with dexamethasone (12 mg on day 1, 4 mg on days 2 and 3)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo with dexamethasone (20 mg on day 1, 8 mg on days 2 and 3)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Aprepitant (day 1, 125 mg; days 2 and 3, 80 mg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 19952817

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) 0.3 g.kg body mass
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium chloride (placebo; PL trial) 0.045 g.kg body mass
Number of subjects: 8
Study: 18639418

Group type: EXPERIMENTAL
Intervention: Endovenous laser treatment
Number of subjects: 98

Group type: COMPARATOR
Intervention: Foam sclerotherapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 98
Study: 17026559

Group type: EXPERIMENTAL
Intervention: Colon preparation on the day of colonoscopy (on-the-day group)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Colon preparation the night before colonoscopy (previous night group)
Number of subjects: 121
Study: 12968982

Group type: COMPARATOR
Intervention: Furosemide (F) 0.5 mg kg(‐1) intravenously
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-salt (HS) diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-salt (LS) diet
Number of subjects: 12